Inventor
JADHAV VASANT
US29 patents
⚠️ This page may combine multiple inventors who share the name “JADHAV VASANT”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
ALNYLAM PHARMACEUTICALS INC
23 patentsUS10612027B2Apr 7, 2020
Modified double-stranded RNA agents
ALNYLAM PHARMACEUTICALS INC26 citations97
US10233448B2Mar 19, 2019
Modified double-stranded RNA agents
ALNYLAM PHARMACEUTICALS INC37 citations97
US10612024B2Apr 7, 2020
Modified double-stranded RNA agents
ALNYLAM PHARMACEUTICALS INC15 citations93
US10208307B2Feb 19, 2019
Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases
ALNYLAM PHARMACEUTICALS INC16 citations93
US11401517B2Aug 2, 2022
Modified double-stranded RNA agents
ALNYLAM PHARMACEUTICALS INC6 citations85
US10513703B2Dec 24, 2019
Hepatitis B virus (HBV) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC6 citations84
US10246713B2Apr 2, 2019
TMPRSS6 iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC6 citations83
US11060091B2Jul 13, 2021
Hepatitis B virus (HBV) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC2 citations73
US11597932B2Mar 7, 2023
Chirally-enriched double-stranded RNA agents
ALNYLAM PHARMACEUTICALS INC3 citations70
US12385044B2Aug 12, 2025
Modified double-stranded RNA agents
ALNYLAM PHARMACEUTICALS INC0 citations62
US12385043B2Aug 12, 2025
Modified double-stranded RNA agents
ALNYLAM PHARMACEUTICALS INC0 citations62
US12378553B2Aug 5, 2025
Modified double-stranded RNA agents
ALNYLAM PHARMACEUTICALS INC0 citations62
US12221607B2Feb 11, 2025
Multi-targeted single entity conjugates
ALNYLAM PHARMACEUTICALS INC0 citations62
US12168767B2Dec 17, 2024
Modified double-stranded RNA agents
ALNYLAM PHARMACEUTICALS INC0 citations62
US11549109B2Jan 10, 2023
Modified double-stranded RNA agents
ALNYLAM PHARMACEUTICALS INC0 citations62
US11427822B2Aug 30, 2022
Modified double-stranded RNA agents
ALNYLAM PHARMACEUTICALS INC0 citations62
US11053495B2Jul 6, 2021
Multi-targeted single entity conjugates
ALNYLAM PHARMACEUTICALS INC0 citations62
US12397013B2Aug 26, 2025
Extrahepatic delivery
ALNYLAM PHARMACEUTICALS INC0 citations61
US12005074B2Jun 11, 2024
Extrahepatic delivery
ALNYLAM PHARMACEUTICALS INC0 citations61
US12018260B2Jun 25, 2024
Tunable Reversir™ compounds
ALNYLAM PHARMACEUTICALS INC0 citations60
US11034957B2Jun 15, 2021
Amyloid precursor protein (APP) RNAi agent compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC1 citations59
US10640770B2May 5, 2020
Hepatitis D virus (HDV) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC0 citations51
US12241064B2Mar 4, 2025
REVERSIR™ compounds
ALNYLAM PHARMACEUTICALS INC0 citations49
SIRNA THERAPEUTICS INC
4 patentsUS7858769B2Dec 28, 2010
RNA interference mediated inhibition of gene expression using multifunctional short interfering nucleic acid (multifunctional siNA)
SIRNA THERAPEUTICS INC156 citations98
US7517864B2Apr 14, 2009
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
SIRNA THERAPEUTICS INC16 citations82
US7521184B2Apr 21, 2009
Detection and quantitation of nucleic acid molecules in biological samples
SIRNA THERAPEUTICS INC17 citations79
US10004814B2Jun 26, 2018
Systemic delivery of myostatin short interfering nucleic acids (siNA) conjugated to a lipophilic moiety
SIRNA THERAPEUTICS INC2 citations69